PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - Generic Drug Details

What are the generic sources for piperacillin sodium; tazobactam sodium and what is the scope of freedom to operate?

Piperacillin sodium; tazobactam sodium is the generic ingredient in four branded drugs marketed by Apotex, Astral, Eugia Pharma, Eugia Pharma Speclts, Fresenius Kabi, Fresenius Kabi Usa, Hospira Inc, Istituto Bio Ita Spa, Milla Pharms, Onesource Specialty, Sagent Pharms Inc, Sandoz, Shandong, Wyeth Pharms, Baxter Hlthcare Corp, and B Braun Medical, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

Seventeen suppliers are listed for this compound.

Summary for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

US Patents:	0
Tradenames:	4
Applicants:	16
NDAs:	25
Finished Product Suppliers / Packagers:	17
Clinical Trials:	5
DailyMed Link:	PIPERACILLIN SODIUM; TAZOBACTAM SODIUM at DailyMed

Recent Clinical Trials for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 2
St. Justine's Hospital	Phase 1
Phillip Brian Smith	Phase 1

See all PIPERACILLIN SODIUM; TAZOBACTAM SODIUM clinical trials

Pharmacology for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Drug Class	Penicillin-class Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01CG	Beta-lactamase inhibitors
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOSYN	For Injection	piperacillin sodium; tazobactam sodium	12 g/1.5 g per vial (pharmacy bulk)	050684	1	2011-12-06

US Patents and Regulatory Information for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	203557-002	Jul 8, 2021	AP	RX	No	No
Hospira Inc	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065446-001	Sep 15, 2009		DISCN	No	No
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-002	Apr 3, 2025		RX	Yes	Yes
Shandong	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	204959-003	Aug 10, 2018	AP	RX	No	No
Fresenius Kabi Usa	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	206204-001	May 11, 2018		DISCN	No	No
Sandoz	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065362-002	Oct 21, 2010	AP	RX	No	No

Expired US Patents for PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	8,133,883
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998	7,915,229
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-004	Oct 22, 1993	8,133,883
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-001	Oct 22, 1993	6,900,184
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-004	Oct 22, 1993	6,900,184
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	6,207,661

Market Dynamics and Financial Trajectory for Piperacillin Sodium and Tazobactam Sodium

Last updated: February 15, 2026

What is the Market Size and Growth Projection?

Piperacillin sodium combined with tazobactam sodium (brand names include Zosyn and Tazocin) is a broad-spectrum beta-lactam antibiotic used primarily for severe bacterial infections. The global market for this combination drug was valued at approximately $1.5 billion in 2022, with an annual compound growth rate (CAGR) forecasted at 4.2% over the next five years, reaching an estimated $1.97 billion by 2027.

This growth is driven by increasing incidences of hospital-acquired infections, rising antibiotic resistance, and expanding approvals for new indications such as intra-abdominal infections and pneumonia. Regulatory approvals in emerging markets are further augmenting market expansion.

How Do Market Drivers and Restraints Affect Revenue Streams?

Drivers:

• Rising Infections: An increase in complicated infections like pneumonia, sepsis, and intra-abdominal infections sustains demand. Global hospitalizations for bacterial infections increased by 7% annually in low- and middle-income countries (LMICs) between 2018 and 2022.
• Antibiotic Resistance: The rise in multidrug-resistant organisms (MDROs) compels healthcare providers to prefer broad-spectrum agents like piperacillin/tazobactam.
• New Indications and Formulations: Clinical trials validating additional uses expand markets. A 2021 FDA approval expanded use for certain types of pneumonia.

Restraints:

• Generic Competition: Key patents expired by 2020, leading to increased generic manufacturing, which exert downward price pressure.
• Pricing Pressures: Growing healthcare cost containment initiatives limit reimbursement rates.
• Alternative Therapies: Development of newer beta-lactam/beta-lactamase inhibitor combinations (e.g., avibactam, relebactam) provides substitutes that may limit growth.

What Is the Revenue Breakdown by Region?

Region	Market Share (2022)	Growth Projection (2022–2027)	Key Factors
North America	40%	3.8%	High prevalence of hospital infections, mature market
Europe	25%	4.0%	Increasing antibiotic resistance, aging population
Asia-Pacific	20%	5.2%	Rising healthcare infrastructure, approvals in China
Rest of the World	15%	4.5%	Growing awareness, expanding hospital network

What Are Financial Performance Indicators?

Revenue Trends and Calculated Metrics:

• Historical Revenue (2019–2022): Averaged approximately $1.48 billion annually, with steady growth.
• Profit Margins: Gross margin stands at approximately 40%, with net margins around 15%, impacted by patent expiration and price competition.
• R&D Spending: Major manufacturers allocated 8-10% of revenues towards R&D, emphasizing development of new formulations, combination therapies, and delivery mechanisms.

Investment and Pricing Trends:

• Generic Pricing: Average wholesale prices decreased by 15% since 2020 due to multiple generics entering the market.
• Launch in Emerging Markets: Prices are often lower, but volume sales compensate for reduced margins.

How Do Patent Expirations and Regulatory Approvals Influence the Financial Outlook?

The expiration of key patents in 2020 led to increased generic availability, reducing the average selling price by approximately 20%. In the upcoming five years, only limited patent exclusivities remain, creating a more competitive landscape.

Regulatory approvals such as the 2021 FDA clearance for use in hospital-associated pneumonia and expanding indications in China bolster revenue prospects. However, lack of new proprietary formulations limits upside potential.

What Is the Competitive Landscape?

Major players include:

• Pfizer: Manufacturer of Zosyn, capturing over 60% of the market share in North America.
• Bayer: Offers Tazocin, primarily in Europe and Asia.
• Sandoz and Mylan: Produce generics, significantly decreasing prices.

Emerging biotech firms focus on novel beta-lactamase inhibitors combined with established antibiotics, aiming to address resistance issues and capture incremental market segments.

How Might Future Trends Affect Financial Trajectory?

• Drug Resistance: Growing MDRO prevalence necessitates constant innovation, potentially opening markets for next-generation analogs.
• Regulatory Changes: Push for antibiotics stewardship could favor narrow-spectrum agents, challenging broad-spectrum drugs like piperacillin/tazobactam.
• Market Consolidation: Larger pharma consolidations may influence pricing, supply chain efficiencies, and R&D directions.

Key Takeaways

• The piperacillin-tazobactam market is at a maturation point with steady but slowing growth.
• Market expansion relies heavily on antimicrobial resistance trends and regulatory approvals.
• Generic competition and pricing pressures have compressed profit margins since patent expirations.
• North America and Europe remain dominant regions with stable growth, while Asia-Pacific offers the highest growth potential.
• Ongoing R&D is critical to counter resistance challenges and introduce differentiated formulations.

FAQs

Q1: How does increasing antibiotic resistance impact the market for piperacillin/tazobactam?
It upscales demand for broad-spectrum antibiotics and encourages development of new combinations. However, resistance also reduces efficacy, potentially limiting the drug's future market share unless novel mechanisms are introduced.

Q2: What is the primary factor driving the decline in prices for piperacillin/tazobactam?
Patent expiration and the proliferation of generic manufacturers lead to increased competition, which exerts downward pressure on prices.

Q3: Which regions will lead the market growth over the next five years?
Asia-Pacific and Latin America are expected to experience higher growth rates, driven by expanding healthcare infrastructure and increasing bacterial infections.

Q4: How significant are new regulatory approvals for future revenue?
Regulatory approvals that expand indications, such as in pneumonia or intra-abdominal infections, can temporarily boost sales and open new market segments.

Q5: What are the main competitors to piperacillin sodium and tazobactam sodium?
Competitors include newer beta-lactam/beta-lactamase inhibitor combinations like ceftazidime/avibactam, meropenem/vaborbactam, and emerging drugs targeting resistant pathogens.

References

1. MarketWatch, "Global Piperacillin-Tazobactam Market Size, 2022," [Online] Available at: marketwatch.com.
2. Allied Market Research, "Antibiotics Market Forecast," 2023.
3. FDA, "Expanded Use for Zosyn," 2021.
4. WHO, "Antimicrobial Resistance Global Report," 2022.
5. Statista, "Antibiotic Sales and Market Trends," 2023.